REPAIR will invest $20–40m per year over three–five years in 20 projects to combat antimicrobial resistance, with the hope that at least one of them will get to market.
The battle to find new antibiotics to replace those that are becoming increasingly ineffective against bacteria has been boosted by the launch of a $165m venture fund set up by Novo Holdings to address the early-stage funding gap.
The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest $20–40m per year over three–five years in about 20 projects involved in the discovery and early-stage development of therapies to combat antimicrobial resistance
Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.
